Cover Image
市場調查報告書

細菌性結膜炎藥物市場:美國的產業分析,開發平台評估,規模,佔有率,成長,趨勢,及2012∼2024年的預測

Bacterial Conjunctivitis Drugs Market - U.S. Industry Analysis, Pipeline Assessment, Size, Share, Growth, Trends and Forecast 2012 - 2024

出版商 Transparency Market Research 商品編碼 364444
出版日期 內容資訊 英文 117 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
細菌性結膜炎藥物市場:美國的產業分析,開發平台評估,規模,佔有率,成長,趨勢,及2012∼2024年的預測 Bacterial Conjunctivitis Drugs Market - U.S. Industry Analysis, Pipeline Assessment, Size, Share, Growth, Trends and Forecast 2012 - 2024
出版日期: 2016年06月15日 內容資訊: 英文 117 Pages
簡介

美國的細菌性結膜炎藥物市場,過去數年戲劇性縮小。一般認為這個趨勢今後也將持續數年。

本報告提供美國的細菌性結膜炎藥物市場相關調查,市場現狀及未來發展預測,各類藥物,開發平台趨勢,及參與企業簡介彙整。

第1章 序論

第2章 摘要整理

第3章 市場概要

  • 市場趨勢和概要
  • 美國的細菌性結膜炎的發病率
  • 推動市場的要素
    • 眼科細菌感染的發病率上升
    • 從新生兒到老年人廣泛的年齡族群容易罹患
  • 阻礙要素
    • 抗菌劑的一般化的擴大導致密集無利益性的市場
    • 專利失效阻礙市場成長
    • 複合的藥物抗性菌阻礙市場成長
  • 市場機會
    • 引進產品開發夥伴關係經營模式
    • 著重並用藥物的設計和對生產
  • 活動影響評估
  • 相關法規
  • 專利和專利的課題
  • API製造商清單
  • 中止的主要產品
  • 市場魅力度分析
  • 市場佔有率分析

第4章 各類藥物市場

  • 概要
  • Fluoroquinolones
  • Aminoglycosides抗生素
  • 大環內酯類
  • 其他

第5章 開發平台評估

  • 概要
  • 萬古霉素(Vancomycin)眼科用軟膏
  • 早期階段

第6章 建議

第7章 企業簡介

  • Actavis plc (now Allergan plc)
  • Akorn, Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Perrigo Company plc
  • Pfizer, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Valeant Pharmaceuticals International, Inc.

圖表

目錄

Bacterial conjunctivitis is a commonly encountered eye problem across the world, caused by various bacterial strains such as streptococci, staphylococci, chlamydial, and gonococci organisms. Majority of the cases of bacterial conjunctivitis are self-limited and acute and not a major cause of morbidity. This study provides market analysis for various antibacterial drug classes used for the treatment of bacterial conjunctivitis. The stakeholders of this study comprise established pharmaceutical companies involved in the commercialization of antibacterial drugs as well as new participants who wish to enter the U.S. market.

This market study provides a complete analysis of the bacterial conjunctivitis drugs market in the U.S. and helps in identifying various market governing factors. The market overview section provides exhaustive information of the incidence rate of bacterial conjunctivitis, list of API manufacturers, patent challenges, market trends such as drivers, restraints, and growth opportunities that currently control the dynamics of the overall market. The section also recommends and predicts the future conditions of the market. Market strategy tools such as event impact assessment and Porter's Five Forces analysis have also been incorporated in this report to provide balanced analysis about the level of competition within the bacterial conjunctivitis drugs market in the U.S. Executive summary provided in the report encapsulates comprehensive insights about every segment considered in this study. Besides, it includes a market snapshot, which offers a glimpse into the current scenario of the bacterial conjunctivitis drugs market in the U.S. in terms of current and future market size along cumulative growth rate. Additionally, this study includes a regulatory framework segment wherein the overall regulatory scenario of the U.S. drugs policy has been described. Participant analysis tools such as market share analysis have also been included in the market overview section of the report to deliver a broad spectrum of the overall market scenario in the bacterial conjunctivitis drugs market in the U.S.

The bacterial conjunctivitis drugs market in the U.S. has been segmented based on various antibacterial drug classes. The market is segmented into major types of antibacterial drugs such as fluoroquinolones, aminoglycosides, macrolides, and others. The fluoroquinolones segment has been sub-segmented into ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, gatifloxacin, and besifloxacin. Aminoglycosides has been sub-segmented into tobramycin and gentamycin. Macrolides has been divided into erythromycin and azithromycin. The others segment is analyzed cumulatively, considering bacitracin, fusidic acid and ceftriaxone within this class. The market size for the period from 2012 to 2024 has been provided for each of the major drug classes mentioned above in terms of USD million. Along with the market size that were projected considering 2013 as the base year and 2012 as the historical year, the CAGR (%) of each market segment for the forecast period from 2012 to 2018 and 2018 to 2024 have also been provided.

The report concludes with detailed profiles of leading players in the bacterial conjunctivitis drugs (antibacterials) market in the U.S. The study profiles the companies in terms of overview, financial overview, product portfolio, business strategies, and recent developments. Major organizations profiled in this report include Actavis plc, Akorn, Inc., Bayer AG, F. Hoffmann-La Roche, Ltd., Merck & Co., Inc., Novartis AG, Perrigo Company plc, Pfizer, Inc., Santen Pharmaceutical Co., Ltd., and Valeant Pharmaceuticals International, Inc. Additionally, market share analysis that has been provided in context with the major pharmaceuticals operating in the market would help new participants to understand the key business perceptions and frameworks and to identify the specific product lines of the existing companies to establish a strong foothold in the bacterial conjunctivitis drugs market in the U.S.

The U.S. bacterial conjunctivitis drugs market is segmented as follows:

U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class

  • Fluoroquinolones
    • Ciprofloxacin
    • Ofloxacin
    • Levofloxacin
    • Moxifloxacin
    • Gatifloxacin
    • Besifloxacin
  • Aminoglycosides
    • Tobramycin
    • Gentamycin
  • Macrolides
    • Erythromycin
    • Azithromycin
  • Others

U.S. Bacterial Conjunctivitis Drugs Market, Pipeline Assessment

  • Vancomycin Ophthalmic Ointment
  • Early Stage (Phase I and Phase II trials) - Tabular Representation

Free Preview

The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market's opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as AzaSite, Zymaxid, Moxeza, and Vigamox, are set to lose their marketing exclusivity very soon.

The growing genericization of antibacterial drugs has impacted the demand for branded drugs significantly. The generic versions of patented formulations, with almost same efficiency as the latter, are easily available at much lower rates in the market. This has increased the sales volume, albeit at the cost of revenues. Many branded ophthalmic drug manufacturers have incurred huge losses due to the generic cannibalization in this market.

Rising Prevalence of MDROs Creates Serious Challenge for Market's Growth

Apart from this, the rising prevalence of multi-drug resistant organisms (MDROs), triggered by wide usage of antibiotics, incorrect drug dosage, and inappropriate medications, has created serious challenges for the treatment of infections such as bacterial conjunctivitis. Researchers across the world are working on discovering efficient drugs for these MDROs. However, the non-availability of effective medications in near future is likely to hamper the market's growth over the coming years.

Although the market is facing a number of restraints at present, it may experience a little relief in future if the product development partnerships (PDPs) models for business are implemented by participants. As various research and development procedures incur a high amount, exerting substantial pressure on pharma companies, strategic alliances with small biotech research organizations will prove to be beneficial for both the parties.

image1

Market Encroachment by Generic Variations to Limit Demand for Topical Fluoroquinolones

Fluoroquinolones, macrolides, and aminoglycosides are the major classes of drugs used for the treatment of bacterial conjunctivitis. The demand for topical fluoroquinolones is the highest among all classes of bacterial conjunctivitis drugs in the U.S. However, the segment is projected to be hindered severely in the coming years, owing to the forthcoming patent expirations of bestselling drugs of this class, such as Vigamox, Moxeza, and Zymaxid by the end of 2016.

The market's opportunity will also be hurt significantly over the next few years due to the encroachment by generic variations of these drugs and decline from US$361.9 mn in 2013 to US$286.4 mn by 2024.

Imminent Patent Expiries to Hurt Leading Players Severely

Valeant Pharmaceuticals Int. Inc., Santen Pharmaceutical Co. Ltd., Pfizer Inc., Perrigo Com. Plc., Novartis AG, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Akorn Inc., and Actavis Plc. are leading the market for bacterial conjunctivitis drugs in the U.S. The imminent patent expiries is likely to hurt the business of these players significantly in the near future. However, the rising prevalence of bacterial infection in eyes and the increasing susceptibility to infection among individuals of various age groups may provide rewarding opportunities to participants over the next few years.

Players are recommended to focus on developing herbal medicines for the treatment of bacterial conjunctivitis, as the consumer preference is shifting from pharmacological medicines to herbal treatment regimens.

Table of Contents

Chapter 1 Preface

  • 1.1 Report Description
  • 1.2 Market Segmentation
  • 1.3 Research Methodology
  • 1.4 Assumptions

Chapter 2 Executive Summary

  • 2.1 Market Snapshot: U.S. Bacterial Conjunctivitis Drugs Market

Chapter 3 U.S. Bacterial Conjunctivitis Drugs Market Overview

  • 3.1 Market Dynamics and Overview
  • 3.2 Incidence Rate of Bacterial Conjunctivitis in the U.S.
  • 3.3 Market Drivers
    • 3.3.1 Rising Incidence of Ophthalmic Bacterial Infection
    • 3.3.2 Susceptibility Among Various Age Groups Ranging from Neonates to Geriatrics
  • 3.4 Market Restraints
    • 3.4.1 Increasing Genericization of Antibacterial Drugs Could Lead to a Crowded and Unprofitable Market
    • 3.4.2 Upcoming Patent Expirations likely to Hinder Market Growth
    • 3.4.3 Burgeoning Multi-Drug Resistant Bacterial Strains Expected To Hinder Market Growth
  • 3.5 Market Opportunities
    • 3.5.1 Implementation of Product Development Partnerships (PDPs) Business Models
    • 3.5.2 Focus on Designing and Producing Combination Drug Products
  • 3.6 Event Impact Assessment: U.S. Bacterial Conjunctivitis Market
  • 3.7 Regulatory Framework
  • 3.8 Patents and Patent Challenges: Overview
  • 3.9 List of API Manufacturers
  • 3.10 Key Discontinued Products: U.S. Bacterial Conjunctivitis Drugs Market
    • 3.10.1 Oxytetracycline/Polymyxin B
    • 3.10.2 Sulfisoxazole Ophthalmic
    • 3.10.3 Phenylephrine/Sulfacetamide Sodium
    • 3.10.4 Chloramphenicol
  • 3.11 Market Attractiveness Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Drug Type
  • 3.12 Market Share Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Key Players, 2013 (Value %)

Chapter 4 U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class

  • 4.1 Overview
    • 4.1.1 Recommended Dosages for Treatment of Bacterial Conjunctivitis
    • 4.1.2 U.S. Bacterial Conjunctivitis Drugs Market Revenue, by Drug Class, 2012 - 2024 (USD Million)
  • 4.2 Fluoroquinolones
    • 4.2.1 Fluoroquinolones for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 - 2024 (USD Million)
    • 4.2.2 Ciprofloxacin
      • 4.2.2.1 U.S. Ciprofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)
    • 4.2.3 Ofloxacin
      • 4.2.3.1 U.S. Ofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)
    • 4.2.4 Levofloxacin
      • 4.2.4.1 U.S. Levofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)
    • 4.2.5 Moxifloxacin
      • 4.2.5.1 U.S. Moxifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)
    • 4.2.6 Gatifloxacin
      • 4.2.6.1 U.S. Gatifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)
    • 4.2.7 Besifloxacin
      • 4.2.7.1 U.S. Besifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)
  • 4.3 Aminoglycosides
    • 4.3.1 Aminoglycosides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 - 2024 (USD Million)
    • 4.3.2 Tobramycin
      • 4.3.2.1 U.S. Tobramycin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)
    • 4.3.3 Gentamycin
      • 4.3.3.1 U.S. Gentamycin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)
  • 4.4 Macrolides
    • 4.4.1 Macrolides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 - 2024 (USD Million)
    • 4.4.2 Erythromycin
      • 4.4.2.1 U.S. Erythromycin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)
    • 4.4.3 Azithromycin
      • 4.4.3.1 U.S. Azithromycin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)
  • 4.5 Others (Bacitracin, Doxycycline, Polymyxin, and Fusidic Acid)
    • 4.5.1.1 U.S. Others Market Revenue, by Bacterial Conjunctivitis, 2012 - 2024 (USD Million)

Chapter 5 U.S. Bacterial Conjunctivitis Drugs Market, Pipeline Assessment

  • 5.1 Overview
  • 5.2 Vancomycin Ophthalmic Ointment
    • 5.2.1 U.S. Vancomycin Ophthalmic Ointment for Bacterial Conjunctivitis Market Revenue, 2019 - 2024 (USD Million)
  • 5.3 Early Stage (Phase I and Phase II trials) - Tabular Representation

Chapter 6 Recommendations

Chapter 7 Company Profiles

  • 7.1 Actavis plc (now Allergan plc)
    • 7.1.1 Company Overview
    • 7.1.2 Financial Overview
    • 7.1.3 Product Portfolio
    • 7.1.4 Business Strategies
    • 7.1.5 Recent Developments
  • 7.2 Akorn, Inc.
    • 7.2.1 Company Overview
    • 7.2.2 Financial Overview
    • 7.2.3 Product Portfolio
    • 7.2.4 Business Strategies
    • 7.2.5 Recent Developments
  • 7.3 Bayer AG
    • 7.3.1 Company Overview
    • 7.3.2 Financial Overview
    • 7.3.3 Product Portfolio
    • 7.3.4 Business Strategies
    • 7.3.5 Recent Developments
  • 7.4 F. Hoffmann-La Roche Ltd.
    • 7.4.1 Company Overview
    • 7.4.2 Financial Overview
    • 7.4.3 Product Portfolio
    • 7.4.4 Business Strategies
    • 7.4.5 Recent Developments
  • 7.5 Merck & Co., Inc.
    • 7.5.1 Company Overview
    • 7.5.2 Financial Overview
    • 7.5.3 Product Portfolio
    • 7.5.4 Business Strategies
    • 7.5.5 Recent Developments
  • 7.6 Novartis AG
    • 7.6.1 Company Overview
    • 7.6.2 Financial Overview
    • 7.6.3 Product Portfolio
    • 7.6.4 Business Strategies
    • 7.6.5 Recent Developments
  • 7.7 Perrigo Company plc
    • 7.7.1 Company Overview
    • 7.7.2 Financial Overview
    • 7.7.3 Product Portfolio
    • 7.7.4 Business Strategies
    • 7.7.5 Recent Developments
  • 7.8 Pfizer, Inc.
    • 7.8.1 Company Overview
    • 7.8.2 Financial Overview
    • 7.8.3 Product Portfolio
    • 7.8.4 Business Strategies
    • 7.8.5 Recent Developments
  • 7.9 Santen Pharmaceutical Co., Ltd.
    • 7.9.1 Company Overview
    • 7.9.2 Financial Overview
    • 7.9.3 Product Portfolio
    • 7.9.4 Business Strategies
    • 7.9.5 Recent Developments
  • 7.10 Valeant Pharmaceuticals International, Inc.
    • 7.10.1 Company Overview
    • 7.10.2 Financial Overview
    • 7.10.3 Product Portfolio
    • 7.10.4 Business Strategies
    • 7.10.5 Recent Developments

List of Figures

  • FIG. 1 U.S. Bacterial Conjunctivitis Drugs Market Segmentation
  • FIG. 1 U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class, 2013 (USD Million)
  • FIG. 2 U.S. Bacterial Conjunctivitis Drugs Market: Drivers, and Restraints
  • FIG. 3 Market Attractiveness Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class
  • FIG. 4 Market Share Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Key Players, 2013 (Value %)
  • FIG. 5 U.S. Ciprofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)
  • FIG. 6 U.S. Ofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)
  • FIG. 7 U.S. Levofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)
  • FIG. 8 U.S. Moxifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)
  • FIG. 9 U.S. Gatifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)
  • FIG. 10 U.S. Besifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)
  • FIG. 11 U.S. Tobramycin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)
  • FIG. 12 U.S. Gentamycin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)
  • FIG. 13 U.S. Erythromycin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)
  • FIG. 14 U.S. Azithromycin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)
  • FIG. 15 U.S. Others Market Revenue, by Bacterial Conjunctivitis, 2012 - 2024 (USD Million)
  • FIG. 16 U.S. Vancomycin Ophthalmic Ointment for Bacterial Conjunctivitis Market Revenue, 2019 - 2024 (USD Million)
  • FIG. 17 Actavis plc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 18 Akorn, Inc.: Annual Revenue, 2011 - 2013 (USD million)
  • FIG. 19 Bayer AG (Bayer HealthCare): Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 20 F. Hoffmann-La Roche Ltd.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 21 Annual Revenue: Merck & Co., Inc., 2011 - 2013 (USD Million)
  • FIG. 22 Novartis AG: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 23 Perrigo Company plc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 24 Pfizer, Inc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 25 Santen Pharmaceutical Co., Ltd.: Annual Revenue, 2011 - 2013 (USD million)
  • FIG. 26 Valeant Pharmaceuticals International, Inc.: Annual Revenue, 2011 - 2013 (USD Million)

List of Tables

  • TABLE 1 Market Snapshot: U.S. Bacterial Conjunctivitis Drugs Market
  • TABLE 2 Upcoming Patents Expiration of Branded Bacterial Conjunctivitis Drugs and Competing Companies of Generic Products
  • TABLE 3 List of Ciprofloxacin API Manufacturers
  • TABLE 4 List of Ofloxacin API Manufacturers
  • TABLE 5 List of Levofloxacin API Manufacturers
  • TABLE 6 List of Moxifloxacin API Manufacturers
  • TABLE 7 List of Gatifloxacin API Manufacturers
  • TABLE 8 List of Besifloxacin API Manufacturers
  • TABLE 9 List of Tobramycin API Manufacturers
  • TABLE 10 List of Gentamycin API Manufacturers
  • TABLE 11 List of Erythromycin API Manufacturers
  • TABLE 12 List of Azithromycin API Manufacturers
  • TABLE 13 List of Bacitracin API Manufacturers
  • TABLE 14 List of Neomycin API Manufacturers
  • TABLE 15 List of Fusidic Acid API Manufacturers
  • TABLE 16 Recommended Dosages for Treatment of Bacterial Conjunctivitis
  • TABLE 17 U.S. Bacterial Conjunctivitis Drugs Market Revenue, by Drug Class, 2012 - 2018 (USD Million)
  • TABLE 18 U.S. Bacterial Conjunctivitis Drugs Market Revenue, by Drug Class, 2019 - 2024 (USD Million)
  • TABLE 19 Fluoroquinolones for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 - 2018 (USD Million)
  • TABLE 20 Fluoroquinolones for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2019 - 2024 (USD Million)
  • TABLE 21 Aminoglycosides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 - 2018 (USD Million)
  • TABLE 22 Aminoglycosides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2019 - 2024 (USD Million)
  • TABLE 23 Macrolides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 - 2018 (USD Million)
  • TABLE 24 Macrolides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2019 - 2024 (USD Million)
  • TABLE 25 Early Stage (Phase I and Phase II trials) - Tabular Representation
  • TABLE 26 Actavis plc: Expenses & Revenue, 2011 - 2013 (USD Million)
  • TABLE 27 Novartis AG: Expenses & Revenue, 2011 - 2013 (USD Million)
Back to Top